 |
Video: What is a Stock Split?
|
 |
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. According to our SLNO split history records, Soleno Therapeutics has had 2 splits. | |
 |

Soleno Therapeutics (SLNO) has 2 splits in our SLNO split history database. The first split for SLNO took place on October 06, 2017. This was a 1 for 5 reverse split, meaning for each 5 shares of SLNO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split. SLNO's second split took place on August 26, 2022. This was a 1 for 15 reverse split, meaning for each 15 shares of SLNO owned pre-split, the shareholder now owned 1 share. For example, a 200 share position pre-split, became a 13.3333333333333 share position following the split.
When a company such as Soleno Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the SLNO split history from start to finish, an original position size of 1000 shares would have turned into 13.3333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Soleno Therapeutics shares, starting with a $10,000 purchase of SLNO, presented on a split-history-adjusted basis factoring in the complete SLNO split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/17/2015 |
|
End date: |
02/12/2025 |
|
Start price/share: |
$182.25 |
|
End price/share: |
$50.25 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-72.43% |
|
Average Annual Total Return: |
-12.09% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$2,758.60 |
|
Years: |
9.99 |
|
|
 |
Date |
Ratio |
10/06/2017 | 1 for 5 | 08/26/2022 | 1 for 15 |
|
 |